NICE Favors Zolgensma Being Added to England’s Public Health Program

NICE Favors Zolgensma Being Added to England’s Public Health Program

295986

NICE Favors Zolgensma Being Added to England’s Public Health Program

England’s National Institute for Health and Care Excellence (NICE) issued its final Zolgensma’s appraisal, recommending that the gene therapy be covered by the country’s national health service (NHS) and provided at low or no cost to eligible spinal muscular atrophy (SMA) patients. The positive recommendation is consistent with England NHS’ March decision to fund the therapy, based on NICE’s draft guidance at the time. The therapy is being administered at different specialized centers, and a first child…

You must be logged in to read/download the full post.